These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11169601)

  • 1. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.
    Gilbert PB
    Stat Med; 2001 Jan; 20(2):263-79. PubMed ID: 11169601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
    Gilbert PB
    Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
    Wick WD; Gilbert PB; Self SG
    PLoS Comput Biol; 2006 Jun; 2(6):e64. PubMed ID: 16789816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials.
    Fiore-Gartland A; Kullman N; deCamp AC; Clenaghan G; Yang W; Magaret CA; Edlefsen PT; Gilbert PB
    Bioinformatics; 2017 Aug; 33(15):2386-2388. PubMed ID: 28379332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
    Longini IM; Datta S; Halloran ME
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
    Gilbert PB; Self SG; Ashby MA
    Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.
    Blower SM; Koelle K; Kirschner DE; Mills J
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3618-23. PubMed ID: 11248127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.
    Longini IM; Hudgens MG; Halloran ME; Sagatelian K
    Stat Med; 1999 Jan; 18(1):53-68. PubMed ID: 9990692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sieve analysis in HIV-1 vaccine efficacy trials.
    Edlefsen PT; Gilbert PB; Rolland M
    Curr Opin HIV AIDS; 2013 Sep; 8(5):432-6. PubMed ID: 23719202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV Vaccine Efficacy Trials: RV144 and Beyond.
    Heger E; Schuetz A; Vasan S
    Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
    Tomaras GD; Plotkin SA
    Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
    Huang Y; DiazGranados C; Janes H; Huang Y; deCamp AC; Metch B; Grant S; Sanchez B; Phogat S; Koutsoukos M; Kanesa-Thasan N; Bourguignon P; Collard A; Buchbinder S; Tomaras GD; McElrath J; Gray G; Kublin JG; Corey L; Gilbert PB
    Curr Opin Virol; 2016 Apr; 17():57-65. PubMed ID: 26827165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.
    Gilbert P; Self S; Rao M; Naficy A; Clemens J
    J Clin Epidemiol; 2001 Jan; 54(1):68-85. PubMed ID: 11165470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.